| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/15/2011 | CA2470703C Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 03/15/2011 | CA2468311C Benzothiazole derivatives |
| 03/15/2011 | CA2432000C Pyrimidineamines as angiogenesis modulators |
| 03/15/2011 | CA2431160C Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 03/15/2011 | CA2426974C Coated medical devices |
| 03/15/2011 | CA2426440C Quinazoline derivatives as kinase inhibitors |
| 03/15/2011 | CA2404196C Medical emulsion for lubrication and delivery of drugs |
| 03/15/2011 | CA2397681C Partially saturated calcium channel blockers |
| 03/15/2011 | CA2394809C Benzazole derivatives and their use as jnk modulators |
| 03/15/2011 | CA2379575C Pharmaceutically active sulfonamide derivatives |
| 03/15/2011 | CA2360415C Benzimidazole vascular damaging agents |
| 03/15/2011 | CA2343009C Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers |
| 03/15/2011 | CA2277192C Nuclear transfer with differentiated fetal and adult donor cells |
| 03/15/2011 | CA2232191C Inhibition of tumor necrosis factor alpha |
| 03/10/2011 | WO2011029102A2 Cd117+cells and uses thereof |
| 03/10/2011 | WO2011028811A2 Dual variable domain immunoglobulins and uses thereof |
| 03/10/2011 | WO2011028737A2 Bisphosphonate compositions and methods for treating heart failure |
| 03/10/2011 | WO2011028651A1 Inhibitors of human 15-lipoxygenase-1 |
| 03/10/2011 | WO2011028416A2 Oral medication for the treatment of hemorrhoids and method of use |
| 03/10/2011 | WO2011028410A2 Topical medication for the treatment of hemorrhoids and method of use |
| 03/10/2011 | WO2011028406A2 Soaking agent for the treatment of hemorrhoids and method of use |
| 03/10/2011 | WO2011028016A2 Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers |
| 03/10/2011 | WO2011027988A2 Novel polymorphic form of prasugrel-hydrogen sulfate |
| 03/10/2011 | WO2011027971A2 Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using same |
| 03/10/2011 | WO2011027956A2 Extracellular vesicles derived from gram-positive bacteria, and disease model using same |
| 03/10/2011 | WO2011027888A1 Diamide-phenyl derivative and pharmaceutically acceptable salt thereof |
| 03/10/2011 | WO2011027839A1 Cholesterol-efflux peptide |
| 03/10/2011 | WO2011027021A1 A method for the treatment of hypertension |
| 03/10/2011 | WO2011026312A1 Novel matrix slow release tablet containing metoprolol succinate |
| 03/10/2011 | WO2011026259A1 Pharmaceutical compositon for anti-thrombotic diseases, its preparation method and use |
| 03/10/2011 | WO2011004402A3 Improved process for the preparation of ambrisentan and novel intermediates thereof |
| 03/10/2011 | WO2010129655A3 Natriuretic polypeptides having mutations within their disulfide rings |
| 03/10/2011 | WO2010117756A3 Substituted benzimidazole pharmaceutical formulations |
| 03/10/2011 | WO2010110596A3 Method for differentiation of stem cells into vascular cells and the induction of angiogenesis using the same |
| 03/10/2011 | WO2010010101A8 Isosorbide nitrates having vasodilating activity |
| 03/10/2011 | US20110061114 Novel pro258 gene disruptions, and methods relating thereto |
| 03/10/2011 | US20110060130 Neutralizing human anti-igfr antibody |
| 03/10/2011 | US20110060041 Method of reversing, preventing, delaying or stabilizing soft tissue calcification |
| 03/10/2011 | US20110060030 Modulation of apolipoprotein c-iii expression |
| 03/10/2011 | US20110060019 Heteroaryl-ureas and their use as glucokinase activators |
| 03/10/2011 | US20110060014 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| 03/10/2011 | US20110060012 4-[3-(aryloxy)benzylidene]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 03/10/2011 | US20110060009 Hydroxamate-Based Inhibitors of Deacetylases |
| 03/10/2011 | US20110060007 Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 |
| 03/10/2011 | US20110060006 Functionally Selective Alpha2C Adrenoreceptor Agonists |
| 03/10/2011 | US20110060005 Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| 03/10/2011 | US20110060001 Thienopyridone derivatives as amp- activated protein kinase (ampk) activators |
| 03/10/2011 | US20110059999 Hydroxymethylcyclohexylamines |
| 03/10/2011 | US20110059996 Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy |
| 03/10/2011 | US20110059993 1-(1-(2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino)-1H-Pyrazolo[4,3-D]Pyrimidin-5-YL) Piperidine-4-Carboxylic Acid And Salts Thereof |
| 03/10/2011 | US20110059992 New Compounds |
| 03/10/2011 | US20110059982 Azaindole compounds for treatment of central nervous system disorders |
| 03/10/2011 | US20110059976 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| 03/10/2011 | US20110059970 4-phenyl-1,3-thiazoles and 4-phenyl-1,3-oxazoles derivatives as cannabinoid receptor ligands |
| 03/10/2011 | US20110059969 Piperazines as anti-obesity agents |
| 03/10/2011 | US20110059968 Carboxamide compounds and their use as calpain inhibitors |
| 03/10/2011 | US20110059966 Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders |
| 03/10/2011 | US20110059964 Pyrazole derivatives and use thereof as orexin receptor antagonists |
| 03/10/2011 | US20110059963 Compounds and methods for kinase modulation, and indications therefor |
| 03/10/2011 | US20110059959 Novel multicyclic compounds and the use thereof |
| 03/10/2011 | US20110059958 Morpholinone compounds as factor ixa inhibitors |
| 03/10/2011 | US20110059957 Benzene or thiophene derivative and use thereof as vap-1 inhibitor |
| 03/10/2011 | US20110059955 Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof |
| 03/10/2011 | US20110059945 S1P Receptor Modulating Compounds and Use Thereof |
| 03/10/2011 | US20110059942 Azetidinyl G-Protein Coupled Receptor Agonists |
| 03/10/2011 | US20110059937 Il-8 receptor antagonists |
| 03/10/2011 | US20110059935 Beta-LACTAMYL VASOPRESSIN V1a ANTAGONISTS |
| 03/10/2011 | US20110059932 Liver x receptor agonists |
| 03/10/2011 | US20110059929 SUBSTITUTED BICYCLIC PIPERIDINYL-AND PIPERAZINYL- SULFONAMIDES USEFUL TO INHIBIT 11beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 |
| 03/10/2011 | US20110059916 Methods and Compositions for Inducing Torpor in a Subject |
| 03/10/2011 | US20110059915 Purine derivatives and methods of use thereof |
| 03/10/2011 | US20110059912 Combination therapy comprising sglt inhibitors and dpp4 inhibitors |
| 03/10/2011 | US20110059896 Use of furin convertase inhibitors in the treatment of fibrosis and scarring |
| 03/10/2011 | US20110059895 Modulation of factor 9 expression |
| 03/10/2011 | US20110059885 Treatment of diseases and conditions mediated by eicosanoids |
| 03/10/2011 | US20110059177 Cardioplegia Solution for Cardiac Surgery |
| 03/10/2011 | US20110059167 Encapsulation of biologically active agents |
| 03/10/2011 | US20110059158 Charged phospholipid compositions and methods for their use |
| 03/10/2011 | US20110059156 Nanostructures Suitable for Sequestering Cholesterol and Other Molecules |
| 03/10/2011 | US20110059147 Long term drug delivery devices with polyurethane based polymers and their manufacture |
| 03/10/2011 | US20110059117 Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same |
| 03/10/2011 | US20110059103 Future cardiac event biomarkers |
| 03/10/2011 | US20110059102 Therapeutic Method Targeting Midkine |
| 03/10/2011 | US20110059089 Protein Markers for Cardiovascular Events |
| 03/10/2011 | US20110059066 PAKs as Modifiers of the CHK Pathway and Methods of Use |
| 03/10/2011 | US20110059059 Methods for Treating Ischemic Tissue |
| 03/10/2011 | US20110059036 Nitric oxide-releasing polymers |
| 03/10/2011 | US20110059010 Dual phase drug release system |
| 03/10/2011 | DE102009040845A1 Blood pressure-lowering beverage comprises blood pressure-lowering biological active substances from plants, fungi and fruits, which are located in a drug-free zone law as a dietary supplement |
| 03/10/2011 | CA2772618A1 Fatty acid niacin conjugates and their uses |
| 03/10/2011 | CA2771770A1 Pcsk9 vaccine |
| 03/09/2011 | EP2292771A2 Sense mRNA therapy |
| 03/09/2011 | EP2292770A2 Methods and means for producing proteins with predetermined post-translational modifications |
| 03/09/2011 | EP2292761A1 Vascular adhesion molecules and modulation of their function |
| 03/09/2011 | EP2292640A2 Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof |
| 03/09/2011 | EP2292631A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 03/09/2011 | EP2292630A1 O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates |
| 03/09/2011 | EP2292622A1 New crystalline form of a triazolo(4,5-d)pyrimidine compound |
| 03/09/2011 | EP2292615A1 Quinazoline compounds |
| 03/09/2011 | EP2292614A1 Substituted pyrimidines as aurora kinase inhibitors |